Atopic asthma is accompanied by chronic eosinophil-rich bronchial mucosal inflammation, the pathogenesis of which is still poorly understood (1, 2) . There is evidence, however, for a critical role for interleukin-5 (IL-5) and other factors orchestrating specific eosinophil accumulation and activation (3) (4) (5) (6) (7) (8) . As a result, tissue damage is believed to be due, at least in part, to the release of toxic granule proteins from activated infiltrating eosinophils (9) . Because IL-5 selectively activates human eosinophils for proinflammatory effector functions (10, 11) , it is reasonable to hypothesize that this cytokine plays a prominent role in asthma. On the other hand, immunoglobulin E (IgE)-mediated release of mediators in sensitized atopic asthmatics after allergen exposure is also thought to be important in directly causing symptoms since allergen exposure provokes acute exacerbations of asthma, whereas removal from exposure ameliorates the disease (12, 13) . IL-4 may also promote tissue eosinophilia by selectively increasing VCAM-1 (the counterligand for VLA-4 on eosinophils) (14) and is an essential cofactor for IgE switching (15) in B-lymphocytes. The relative contributions of IL-5 (in promoting tissue eosinophilia) and IL-4 (additionally regulating IgE) to the pathogenesis of atopic asthma remains unclear (16) .
In the present study, we chose to focus on the expression of IL-5 and IL-4 mRNA in the bronchial mucosa of a group of asthmatics in whom we had stringently documented disease severity and atopic status. We reasoned that if both cell-mediated and IgE-mediated mechanisms are important in pathogenesis, then disease severity should reflect local expression of both IL-5 and IL-4, pivotal cytokines regulating cell-mediated eosinophil recruitment and IgE synthesis, respectively. We and others (17) (18) (19) have previously shown that both IL-5 and IL-4 mRNA expression within the bronchial mucosa is elevated in atopic asthmatics as compared with atopic and nonatopic nonasthmatic control subjects. In order further to analyze the possible role of these cytokines in atopic asthma, we hypothesized that the copy numbers of both IL-5 and IL-4 mRNA (relative to those of the "housekeeping" gene ␤ -actin) within the bronchial mucosa correlates with validated indicators of disease severity.
METHODS

Patient Population
Bronchial biopsies were obtained at fiberoptic bronchoscopy from 10 atopic asthmatics. Asthma was defined as ( 1 ) a clear clinical history with current symptoms, ( 2 ) evidence of more than 20% reversibility of the FEV 1 , either spontaneously or after inhaled beta-2 agonists and/or a histamine PC 20 provocation test of р 4 mg/ml during the previous 2 wk. Full clinical examination, lung function testing (FVC, FEV 1 , and FEV 1 /FVC ratio), histamine PC 20 , skin prick testing, chest radiograph, full blood count, total serum IgE, and RAST were obtained in all patients prior to bronchoscopy. Morning and evening PEFR (L/min) were measured before bronchodilator inhalation for 14 d, and the ratio (R) ϭ PEFR max Ϫ PEFR min /PEFR max was calculated (PEFR variability over 2 wk). Asthma severity was also assessed according to the five-point scale scoring system of Aas (20) .
Atopy was defined by a positive skin prick test to extracts of one or more aeroallergens (including house dust mite, mixed grass pollen, mixed tree pollen, mixed moulds, cat fur, and dog dander) (Soluprick; ALK-Abello, Horsholm, Denmark). Using the Phadebas system (Pharmacia Diagnostics, Uppsala, Sweden) all atopics demonstrated elevated serum allergen-specific IgE concentrations Ͼ 0.70 IU/ml to one or more of these allergens. All subjects were nonsmokers and had not taken oral corticosteroids for the previous 2 mo, or inhaled corticosteroids for the previous 2 wk. Exclusion criteria included age Ͻ 18 yr or Ͼ 65 yr, FEV 1 Ͻ 50% of the predicted value on the proposed bronchoscopy day, evidence of acute or chronic infection, pregnancy, breast-feeding, or any chronic medical illness other than asthma. The study was approved by the Ethics Committee of the Royal Brompton Hospital, London, and all patients and volunteers gave written informed consent.
Fiberoptic Bronchoscopy
All subjects (asthmatics and controls) underwent bronchoscopy with bronchial biopsies as previously described (21) . Bronchial biopsies were snap-frozen and stored at Ϫ 80 Њ C to be used later for RT-PCR.
Reverse Transcriptase-Polymerase Chain Reaction
Semiquantitative RT-PCR reactions were performed as previously described (19) . All reagents were from Sigma Chemicals (Poole, UK), unless otherwise indicated. Bronchial biopsies were thawed and homogenized (Omni 1000 homogenizer; Camlab, Cambridge, UK) in TRI Reagent (1 ml) containing Microcarrier Gel (4 l) (both from Molecular Research Center Inc., Oxford, UK), and total RNA was extracted according to the manufacturer's instructions. The RNA was reverse-transcribed (total volume, 40 l) using oligo-dT12-18 primers (Pharmacia) and M-MLV reverse transcriptase (Gibco BRL, Paisley, UK) as previously described (19) . Reverse transcribed mRNA was stored at Ϫ 80 Њ C until used for PCR amplification.
For PCR amplification, 5-l aliquots of 1:20 diluted reverse transcription mixture from all subjects were made up to 40 l in reverse transcription PCR buffer containing 1.25 mM primers (Clontech, Palo Alto, CA) and 2.5 U of Taq polymerase (BRL). Samples were overlaid with mineral oil and transferred to a thermal cycler (Hybaid, Teddington, UK). After denaturing (at 94 Њ C for 5 min), samples were subjected to 40 (IL-4, IL-5) or 36 ( ␤ -actin) cycles of denaturation (at 94 Њ C for 1 min), annealing (at 60 Њ C for 2 min), and extension (at 72 Њ C for 3 min), followed by a final extension step (at 72 Њ C for 5 min). The primers used were as follows: PCR 5 Ј primers: AAG GCC AAC CGC GAG AAG ATG ( ␤ -actin), CGG CAA CTT TGA CCA CGG ACA CAA GTG CGA TA (IL-4), and GCT TCT GCA TTT GAG TTT GCT AGC T (IL-5); PCR 3 Ј primers: ACA GGA CTC CAT GCC CAG GAA ( ␤ -actin), ACG TAC TCT GGT TGG CTT CCT TCA CAG GAC AG (IL-4), and TGG CCG TCA ATG TAT TTC TTT ATT AAG (IL-5). All primers spanned at least one genomic intron. The expected product sizes were 480 bp ( ␤ -actin), 344 bp (IL-4), and 294 bp (IL-5). Serial 10-fold dilutions of control cDNA, starting from a maximal number of copies of 1.5 ϫ 10 8 (2.5 ϫ 10 Ϫ 16 mole) (Clontech) were amplified along with samples from the subjects.
The size and purity of PCR amplified products were verified by preliminary agarose gel electrophoresis. To semiquantify each PCRamplified cDNA, 10 l of PCR amplification mixture from all subjects were denatured, Southern blotted, and probed with internal oligonucleotides. The probes were end-labeled (specific activities, 9.6 to 15.5 ϫ 10 6 cpm/ng) with ␥ 32 P-ATP (Amersham, Buckinghamshire, UK) using T4 polynucleotide kinase then purified on Sepharose G20 (Pharmacia) centrifuge columns. The probe sequences were as follows:
GGC TGG GGT GTT GAA GGT CTC AAA CAT GAT ( ␤ -actin), GTC CTT CTC ATG GTG GCT GTA GAA CTG CCG (IL-4), and ATT TTT ATG TAC AGG AAC AGG AAT CCT CAG (IL-5). After a high-stringency wash the membranes were exposed for a time period sufficient to allow visualization of the blots but not to saturate the autoradiographs.
Autoradiographs were scanned using a flat bed scanner and associated software (Quantity One Software; PDI Inc., New York, NY) to measure the areas under the densitometry peaks. Standard curves relating the areas of the blots produced by amplification of the serial 10-fold dilutions of the cDNA standards (IL-4, IL-5, ␤ -actin) to their starting concentrations were constructed. In each case, the logarithms of the blot areas were approximately linearly related to the starting concentrations of the cDNA standards within the ranges of concentrations measured in the samples from the subjects, as predicted by the exponential nature of PCR amplification under nonsaturating conditions. No signal was obtained from blotted irrelevant cDNA controls. The areas of the blots from each amplified cDNA sample from the subjects were then expressed in terms of the numbers of starting copies of standard cDNA required to produce a blot of the same area. Finally, for each subject sample the numbers of starting copies of IL-4 and IL-5 cDNA were expressed as percentages of the numbers of starting copies of ␤ -actin cDNA.
Statistical Analysis
Data were analyzed nonparametrically using a statistical package (Minitab Release 7; Minitab Inc., State College, PA). Median values and ranges are indicated in R ESULTS . The Mann-Whitney U test was then used for intergroup comparison. Correlation coefficients were obtained by Spearman's rank-order method.
RESULTS
IL-5 mRNA was detected by semiquantitative RT-PCR in bronchial biopsies from atopic asthmatics (median, 154% ␤ -actin mRNA; range, 0 to 443). In these patients, IL-5 mRNA expression (relative to ␤ -actin mRNA) was higher in patients with the more severe symptoms (Aas asthma score 4 versus Aas asthma score 1 to 3, p ϭ 0.01) (Figure 1) . Moreover, IL-5 mRNA expression (relative to ␤ -actin mRNA) positively correlated with the Aas asthma score (r ϭ 0.70, p ϭ 0.01) and peak expiratory flow rate variability over 2 wk (r ϭ 0.69, p ϭ 0.028), and inversely correlated with the patients' bronchial responsiveness as measured by histamine PC 20 (r ϭ 0.72, p ϭ 0.018), baseline FEV 1 (r ϭ 0.94, p ϭ 0.001), FEV 1 /FVC ratio (r ϭ Ϫ 0.72, p ϭ 0.018), and baseline peak expiratory flow rate (r ϭ 0.77, p ϭ 0.001) (Figures 2 and 3) . Conversely, IL-5 mRNA expression (relative to ␤ -actin mRNA) did not correlate with serum IgE concentrations (p Ͼ 0.25).
IL-4 mRNA was detected by semiquantitative RT-PCR in bronchial biopsies from atopic asthmatics (median, 153% ␤ -actin mRNA; range, 0 to 893). In the atopic asthmatics, IL-4 mRNA expression (relative to ␤ -actin mRNA) positively correlated with serum IgE concentrations (r ϭ 0.90, p ϭ 0.001) (Figure 4) . Conversely, IL-4 mRNA expression (relative to ␤ -actin mRNA) was not greater in patients with the more severe symptoms, and IL-4 mRNA expression did not correlate with the patients' baseline FEV 1 , baseline peak expiratory flow rate, peak expiratory flow rate variability over 2 wk, and bronchial responsiveness as measured by histamine PC 20 (p Ͼ 0.25).
DISCUSSION
In this study we have shown that bronchial mucosal IL-5 mRNA expression (relative to ␤ -actin mRNA) in atopic asthmatics correlated with several objective measures of asthma severity. In contrast, IL-4 mRNA expression (relative to ␤ -actin mRNA) did not correlate with any of these asthma variables, although there was a significant association with total serum IgE concentrations.
As discussed above, we hypothesized that IL-5 mRNA expression reflects a T-cell-mediated hypersensitivity reaction leading to eosinophil recruitment, whereas IL-4 mRNA expression reflects IgE synthesis. As our PCR technique required homogenization of biopsy material, we were unable to correlate IL-5 mRNA expression and bronchial mucosal eosinophil counts. However, previous reports have shown that IL-5 mRNA expression in the asthmatic bronchial mucosa correlated with the numbers of eosinophils within the mucosa (2, 17) . Moreover, the numbers of eosinophils in the asthmatic bronchial mucosa have been shown in many other studies to correlate with disease severity (1, 2) . Taken together with the recognized eosinophil-specific biologic activities of IL-5 (3, 10, 11), these observations provide strong support for the hypothesis that IL-5 regulates asthma severity through eosinophil recruitment.
IL-4 is one of two cytokines known to cause IgE-switching in B-cells, a prerequisite for elevated IgE synthesis (15) , and by inference in the pathogenesis of atopy. Our data do not support the hypothesis that increased IL-4 synthesis regulates disease severity in atopic asthma. Our data do not confirm an initial report that did show a significant association between the numbers of bronchoalveolar lavage cells expressing mRNA for IL-4 (using in situ hybridization) and disease severity in atopic asthma (18) . It is, however, important to emphasize that although in situ hybridization can identify gene expression in discrete cells, the numbers of mRNA ϩ cells only gives an estimate of the proportion of cells within the sample that transcribe cytokine genes, not the total number of copies of mRNA per cell. We have recently demonstrated that RT-PCR was a more sensitive method than in situ hybridization for detecting bronchial mucosal cytokine mRNA expression (19) . Therefore, a validated semiquantitative RT-PCR technique provides a more accurate method of analyzing IL-4 and IL-5 mRNA expression in asthma. It is important to note that our data do not preclude the possibility that asthma may be exacerbated acutely by IgE-mediated release of mast cell mediators after acute allergen exposure since this results in local release of bronchoconstrictor substances in hyperresponsive airways. On the other hand, this does not necessitate an obligatory role for IL-4/IgE in the pathogenesis of chronic asthma.
Implicit in our arguments is the assumption that IL-4 and IL-5 mRNA expression within the asthmatic bronchial mucosa is translated into active protein. Although this cannot be assumed, we have recently demonstrated expression of IL-4 and IL-5 protein in the bronchial mucosa of both atopic and nonatopic asthmatics (19) , which strongly suggests mRNA translation, although the translation rate and efficiency for individual cytokines may vary. Recently, an alternatively spliced transcript of human IL-4, which lacks exon 2 and functions as an IL-4 antagonist (22, 23), has been described. Such a variant, if present in our samples, would have been detected by our PCR protocol as an amplification product of shorter length (296 bp) than that produced by amplification of full-length IL-4 mRNA. Although we could detect no such products on preliminary sizing gels, the amplification product from this variant would have been expected to hybridize with our IL-4 probe in the Southern blotting procedure, and we cannot rule out the possibility that it may have been present at low copy numbers.
Our observed correlation between bronchial mucosal IL-4 mRNA expression and serum IgE concentrations in atopic asthmatics is compatible with the hypothesis that the maintenance of elevated IgE synthesis in these patients is at least partly IL-4-dependent. This cannot be assumed a priori because of the potential longevity of activated B-cell clones, which might continue (perhaps for years) to produce IgE after IL-4-dependent switching in an IL-4-independent manner. The data are also compatible with the hypothesis that ongoing IgE synthesis in atopic asthmatics, if present, occurs actually within the bronchial mucosa itself, but on the other hand do not exclude the possibility that cytokines may exert their ac- tivities at least partially in immune compartments not accessible to bronchial biopsy such as regional lymph nodes. These important questions should be addressed in future studies.
Our data do not support a role for IL-4 in regulating disease symptoms and severity in atopic asthma. Nevertheless local IL-4 synthesis may still play some role in directing local differentiation of T-cells towards a "Th2-type" (IL-5 producing) phenotype (24) . On the other hand IL-4 expression in this situation may simply reflect a surrogate marker of "Th2-type" T-cell activation, although recent studies suggest that coexpression of IL-5 and IL-4 by individual T-cells is not always obligatory (25) .
In summary our data strongly implicate IL-5 as a major molecular target in atopic asthma, whereas the role of IL-4 is less clear. The effects of specific IL-5 and IL-4 antagonists in ameliorating human asthma will give more specific answers to these questions (26) . Indirect approaches, based on studies of "models" of asthma in cytokine-deficient mice sensitized and challenged with aerosolized proteins have provided interesting information regarding lung eosinophilic inflammatory responses (15, (27) (28) (29) . A problem with such "models" is that since the precise mechanism of bronchial hyperreactivity in human asthma is unknown, it is difficult to assume that experimental manipulations that produce bronchial hyperreactivity in animals, although arguably physiologically similar to that observed in humans, are also pathogenetically similar. Therefore, studies designed to dissect the respective roles of putatively important cytokines in human asthma are still critical to improve our knowledge of the disease.
